What liver disease is Madrigal Pharmaceuticals targeting with its new drug programs?

Madrigal Pharmaceuticals is targeting metabolic dysfunction-associated steatohepatitis (MASH) with its new drug programs.

Who did Madrigal Pharmaceuticals partner with for the new siRNA programs?

Madrigal Pharmaceuticals partnered with China-based Suzhou Ribo Life Science and its unit Ribocure for the six preclinical siRNA programs.

What is the potential value of the licensing agreement between Madrigal and Suzhou Ribo?

The licensing agreement could reach up to $4.4 billion if certain development, regulatory, and commercial milestones are met, in addition to an upfront payment and royalties.

Home / Health / Madrigal Pharma Strikes $4.4B Deal for Liver Disease Drugs

Madrigal Pharma Strikes $4.4B Deal for Liver Disease Drugs

11 Feb

•

Summary

Madrigal Pharmaceuticals secured global rights to six preclinical siRNA programs.
The deal with Suzhou Ribo Life Science could reach up to $4.4 billion.
The therapies aim to treat metabolic dysfunction-associated steatohepatitis (MASH).

Madrigal Pharma Strikes $4.4B Deal for Liver Disease Drugs

Madrigal Pharmaceuticals announced on February 11, 2026, that it has secured an exclusive global license for six preclinical small interfering RNA (siRNA) programs. The agreement was made with Suzhou Ribo Life Science and its subsidiary Ribocure, both based in China.

These siRNA programs are being developed to treat metabolic dysfunction-associated steatohepatitis (MASH), a severe liver condition that can lead to cirrhosis, liver failure, and cancer. Madrigal will have exclusive rights to develop, manufacture, and commercialize these compounds worldwide.

Suzhou Ribo Life Science will receive an initial payment of $60 million. The total value of the agreement could potentially reach $4.4 billion, contingent upon the successful achievement of specific development, regulatory, and commercial milestones. Additionally, Suzhou Ribo will benefit from future net sales through royalty payments.